Home  ›  4 Review Conflict-of-interest Statements Obtained by the Company for Its Management

4 Review Conflict-of-interest Statements Obtained by the Company for Its Management

Written By Saturday, 16 April 2022 Add Comment Edit

Overview of conflicts of interest in academic publishing

Conflicts of involvement (COIs) ofttimes arise in academic publishing. Such conflicts may cause wrongdoing and brand information technology more than probable. Upstanding standards in academic publishing exist to avoid and deal with conflicts of interest, and the field continues to develop new standards. Standards vary between journals and are unevenly applied. Co-ordinate to the International Committee of Medical Journal Editors, "[a]uthors have a responsibility to evaluate the integrity, history, practices and reputation of the journals to which they submit manuscripts".[1]

Conflicts of interest increase the likelihood of biases arising; they can harm the quality of enquiry and the public good (even if disclosed).[2] Conflicts of interest tin can involve research sponsors, authors, journals, journal staff, publishers, and peer reviewers.

Avoidance, disclosure, and tracking [edit]

The avoidance of conflicts of interest and the changing of the structure of institutions to make them easier to avoid are frequently advocated for. Some institutional ethics policies ban academics from inbound into specific types of COIs, for instance by prohibiting them from accepting gifts from companies connected with their work.[iii] Education in ethical COI direction is also a tool for avoiding COI problems.[3]

Disclosure of COIs has been debated since the 1980s; there is a general consensus favouring disclosure.[two] There is likewise a view that COI concerns and some of the measures taken to reduce them are excessive.

Criticisms of disclosure policies include:

  • authors disclosing COIs may experience pressured to nowadays their research in a more biased manner to compensate;[2]
  • disclosure may discourage beneficial bookish–industrial collaboration;[four]
  • disclosure may decrease public trust in research;[iv]
  • researchers who have disclosed their COIs may feel license to bear immorally;[iv] [5]
  • disclosure may be taken equally a sign of honesty or expertise and thus increment trust;[4]
  • some types of COI may be more likely than others to go unnoticed or unreported;[4]
  • awareness of a COI does non make people immune to being influenced by bias; generally, people do not sufficiently discount biased advice;[4] [5]
  • disclosure discourages the judging of piece of work purely on its merits;[4]
  • disclosure causes more intense scrutiny for wrongdoing.[4]

While disclosure is widely favoured, other COI management measures have narrower support. Some publications hold the stance that certain COIs disqualify people from certain research roles; for instance, that the testing of medicines should be done only by people who neither develop medicines nor are funded by their manufacturers.[2] [5]

Conflicts of involvement have also been considered as a statistical factor confounding prove, which must therefore exist measured every bit accurately as possible and analysed, requiring machine-readable disclosure.[2]

Codes of acquit [edit]

Journals take individual ethics policies and codes of conduct; there are also some cross-journal voluntary standards.

The International Committee of Medical Journal Editors (ICMJE) publishes Recommendations for the Behave, Reporting, Editing, and Publication of Scholarly piece of work in Medical Journals, and a list of journals that pledge to follow it. The guideline lays down detailed rules for conflict-of-interest declaration by authors. It also says; "All participants in the peer-review and publication procedure—not only authors simply besides peer reviewers, editors, and editorial board members of journals—must consider their conflicts of interest when fulfilling their roles in the process of commodity review and publication and must disclose all relationships that could be viewed equally potential conflicts of involvement".[1] These recommendations have been criticized and revised to remove loopholes allowing the non-disclosure of conflicts of interest.[6]

The Quango of Science Editors publishes a White Paper on publication ideals. Citing the ICMJE that "all participants in the peer-review and publication procedure must disclose all relationships that could be viewed every bit potential conflicts of interest", it highly recommends COI disclosure for sponsors, authors, reviewers, journals, and editorial staff.[seven]

The Good Publication Exercise (GPP) guidelines, covering manufacture-sponsored medical enquiry, are published by the International Society of Medical Publication Professionals.[8]

The Committee on Publication Ethics (COPE) publishes a code of conduct stating, "[t]here must be clear definitions of conflicts of involvement and processes for handling conflicts of interest of authors, reviewers, editors, journals and publishers, whether identified before or after publication".[9]

The Open Access Scholarly Publishers Association's Principles of Transparency and Best Practice in Scholarly Publishing is intended to split up legitimate journals from predatory publishers[x] and defines a minimal standard; articulate and clearly stated COI policies.[11]

A 2009 Us Institute of Medicine report on medical COIs states that conflict-of-interest policies should exist judged on their proportionality, transparency, accountability, and fairness; they should be effective, efficient, and targeted, known and understood, conspicuously place who is responsible for monitoring, enforcement, and amendment, and utilise equally to everyone involved. Review by conflict-of-involvement committees is besides recommended, and the lack of transparency and COI declaration in developing COI guidelines criticized.[three]

As of 2015[update], journal COI policies ofttimes have no enforcement provisions.[12] COI disclosure obligations take been legislated; ane example of such legislation is the Us Dr. Payments Sunshine Act, but these laws do not utilize specifically to journals.[iii]

COIs by agent [edit]

COIs of journals [edit]

Journals are often not transparent nearly their institutional COIs, and practice not utilize the aforementioned disclosure standards to themselves as they do to their authors.[xiii] [14] Four out of vi major general medical journals that were contacted for a 2010 COI written report refused to provide information most the proportion of their income that derived from advertisements, reprints, and manufacture-supported supplements, citing policies on non-disclosure of financial data.[14]

Owners and governing bodies [edit]

The possessor of an academic journal has ultimate power over the hiring and firing of editorial staff;[15] editors' interests in pleasing their employers disharmonize with some of their other editorial interests.[16] [17] Journals are also more likely to accept papers by authors who work for the journals' hosting institutions.[xviii] [19]

Some journals are owned past publishers. When journals print reviews of books published past their ain publishers, they rarely (as of 2013[update]) add COI disclosures.[xx] The publishers' interest in maximizing profit will ofttimes disharmonize with academic interests or ethical standards. In the case of airtight-access publications, publishers' desire for high subscription income may conflict with an editorial desire for broader access and readership. There have been multiple mass resignations of editorial boards over such conflicts,[21] which are often followed by the editorial board founding a new, non-profit journal to compete with their one-time 1.[22]

Some journals are owned by bookish societies and professional organisations. Leading journals can be very assisting[23] [24] and there is often friction nearly revenue betwixt the journal and the member society that owns information technology.[23] [15] [24] Some academic societies and professional person organisations are themselves funded by membership fees and/or donations. If the owners benefit financially from donations, the periodical has a conflict between its financial interest in satisfying the donors—and therefore the owners—and its journalistic interests. Such COIs with manufacture donors have fatigued criticism.[25]

Reprints [edit]

A reprint is a copy of an individual commodity[26] that is printed and sold every bit a separate production by the journal or its publisher or agent.[xiv] [16] Reprints are frequently used in pharmaceutical marketing and other medical marketing of products to doctors.[26] This gives journals an incentive to produce skillful marketing material.[14] [sixteen] Journals sell reprints at very high turn a profit margins, often around 70%, as of 2010[update]. A periodical may sell a meg dollars worth of reprints of a single commodity if, for example, it is a large manufacture-funded clinical trial.[24] The selling of reprints can bring in over forty% of a periodical's income.[xiv]

Impact factors, reputation, and subscriptions [edit]

If a journal is accused of managing COIs badly, its reputation is harmed.[27]

The touch on factor of a journal is often used to charge per unit it, although this practice is widely criticized. A journal will generally want to increase its impact factor in hope of gaining more than subscriptions, better submissions, and more prestige.[24] As of 2010, industry-funded papers generally go cited more than than others; this is probably due in part to industry-paid publicity.[14] [17]

Some journals appoint in coercive citation, in which an editor forces an author to add extraneous citations to an article to inflate the impact factor of the journal in which the extraneous papers were published.[28] [29] A survey found that 86% of academics consider coercive citation unethical merely 20% have experienced it. Journals appear to preferentially target younger authors and authors from non-English-speaking countries. Journals published by for-turn a profit companies used coercive commendation more than those published past university presses.[30]

Journals may find information technology hard to correct and retract erroneous papers after publication because of legal threats.[31] [32]

Advertising [edit]

Many academic journals contain advertising. The portion of a periodical'south acquirement coming from advertising varies widely, according to one small study, from over fifty% to ane%.[14] As of 2010, advertising revenues for academic journals are mostly falling.[24] A 1995 survey of North American journal editors found that 57% felt responsible for the honesty of the pharmaceutical advertisements they ran and 40% supported peer-review of such advertisements.[16] An interest in increasing advertisement acquirement can conflict with interests in journalistic independence and truthfulness.

[edit]

As of 2002, some journals publish supplements that often either cover an manufacture-funded conference or are "symposia" on a given topic. These supplements are often subsidized by an external sponsor with a financial interest in the outcome of research in that field; for instance, a drug manufacturer or food industry group. Such supplements can accept guest editors,[1] are often not peer-reviewed to the aforementioned standard equally the journal itself, and are more than probable to use promotional language.[16] Many journals do not publish sponsored supplements.[14] Pocket-size-circulation journals are more probable to publish supplements than big, loftier-prestige journals.[33] Indications that an article was published in a supplement may be adequately subtle; for instance, a alphabetic character "due south" added to a page number.[34]

The ICMJE code of behave specifically addresses invitee-editor COIs; "Editors should publish regular disclosure statements almost potential conflicts of interests related to their own commitments and those of their journal staff. Guest editors should follow these aforementioned procedures." It also states that the usual journal editor must maintain full command and responsibility and that "Editing by the funding organization should non exist permitted".[ane]

The US Food and Drug Administration states that supplement manufactures should non exist used as medical-marketing reprints simply as of 2009[update] it had no legal authority to prohibit the practice.[26]

Publishers [edit]

Publishers may not be strongly motivated to ensure the quality of their journals. In the Australasian Journal of Bone & Joint Medicine case, the printer Elsevier Commonwealth of australia put out six journal-similar publications containing articles nearly drugs fabricated by the Merck Group, which paid for and controlled the publications.[35]

COIs of journal staff [edit]

Personal conflicts of interest faced by journal staff are individual. If a person leaves the periodical—unlike the COIs of journals as institutions—their personal COIs will go with them.

As of 2015[update], COIs of journal staff are less normally reported than those of authors.[12] For instance, one 2009 World Association of Medical Editors (WAME) policy certificate states, "Some journals list editors' competing interests on their website but this is not a standard practice".[36] The ICMJE, still, requires that the COIs of editors and periodical staff be regularly declared and published.[one]

I 2017 Open Payments written report of influential US medical journals plant half of the editors received payments from manufacture;[37] another study that used a different sample of editors reported two-thirds.[38] As of 2002[update], systems for reporting wrongdoing by editors often practice not exist.[sixteen]

Many journals accept policies limiting COIs staff can enter into; for instance, accepting gifts of travel, accommodation, or hospitality may be prohibited. As of 2016[update], such policies are rarely published.[39] Most journals do not offering COI training; as of 2015[update], many journals report a desire for better guidance on COI policy.[12]

COIs of peer reviewers [edit]

The ICJME recommendations require peer reviewers to disclose conflicts of interest.[one] Half to two-thirds of journals, depending on subject surface area, did not follow this recommendation in the first 2 decades of the 21st century.[40] As of 2017[update], if a peer reviewer fails to disclose a disharmonize of interest, the paper will by and large non be withdrawn, corrected, or re-reviewed; the reviews, however, may be reassessed.[41]

If peer reviewers are bearding, their COIs cannot be published. Some experiments with publishing the names of reviewers have been undertaken; in others, the identities of reviewers were disclosed to authors, allowing authors to identify COIs.[42] Some journals now accept an open up review process in which everything, including the peer reviews and the names of the reviewers, and editor and author comment, is published transparently online.[37]

The duties of peer review may conflict with social interests or institutional loyalties; to avoid such COIs, reviewers may be excluded if they have some forms of COI, such as having collaborated with the writer.[forty]

Readers of academic papers may spot errors, informally or equally role of formal post-publication peer review. Academics submitting corrections to papers are often asked by the publishers to pay over 1,000 US dollars for the publication of their corrections.[31]

[edit]

Authors of individual papers may confront conflicts with their duty to report truthfully and impartially. Financial, career, political, and social interests are all sources of disharmonize.[36] Authors' institutional interests become sources of conflict when the research might harm the institution's finances or offend the author's superiors.[3]

Many journals require authors to cocky-declare their conflicts of interest when submitting a newspaper; they also ask specific questions about conflicts of interest. The questions vary substantially betwixt journals.[39] Author declarations, withal, are rarely verified by the periodical. As of 2018, "most editors say it'due south not their job to make certain authors reveal fiscal conflicts, and there are no repercussions for those who don't".[43] Even if a conflict of involvement is reported by a reader afterwards publication, COPE does not propose independent investigation, as of 2017[update].[44]

As a upshot, as of 2018[update], authors oftentimes fail to declare their conflicts of interest.[45] [43] Rates of nondisclosure vary widely in reported studies.[two]

The COPE retraction guidelines land, "Retractions are besides used to alert readers to ... failure to disclose a major competing involvement probable to influence interpretations or recommendations".[46] As of 2018[update], nevertheless, if an author fails to disclose a COI, the paper volition usually be corrected;[47] it will not commonly exist retracted.[48] Paper retractions, notifications to superiors, and publication bans are possible. Non-disclosure incidents harm academic careers.[47] Authors are held to have commonage responsibility for the contents of an article;[49] if one writer fails to declare a conflict of interest, the peer review process may be accounted compromised and the whole paper retracted.

The publisher may charge authors substantial fees for retracting papers, even in cases of honest error, giving them a fiscal disincentive to correct the tape.[31]

Public registries of author COIs have been suggested.[two] Authors face up authoritative burdens in declaring COIs; standardized declarations[3] or a registry could reduce these.[2]

Ghost authors and non-contributing authors [edit]

Ghost authorship, where a writer contributes simply is non credited, has been estimated to affect a significant proportion of the enquiry literature. Honorary authorship, where an writer is credited just did not contribute, is more than common.[50] Being named as an author on many papers is good for an academic's career. Failure to attach to authorship standards is rarely punished.[50] To avoid misreported authorship, a requirement that all authors describe the contribution they fabricated to the study ("picture show-way credits") has been advocated for.[51] Ghostwriters may exist legally liable for fraud.[52] [53]

The ICMJE criteria for authorship require that authors contribute:

  • Substantial contributions to the formulation or design of the piece of work; or the conquering, analysis, or estimation of data for the work; and
  • Drafting the piece of work or revising it critically for of import intellectual content; and
  • Final approval of the version to exist published; and
  • Agreement to be accountable for all aspects of the piece of work in ensuring that questions related to the accuracy or integrity of any function of the work are appropriately investigated and resolved.[49]


The ICMJE requires that "All those designated every bit authors should meet all four criteria for authorship, and all who meet the four criteria should exist identified every bit authors. Those who do non run across all four criteria should be best-selling."[49] Academics who have had publication ethics training and those who are aware of the ICMJE authorship criteria are more than stringent in their concepts of authorship and are more than likely to consider breaches of authorship as misconduct, as are more junior researchers. Awareness is low; i study establish just well-nigh one-half of researchers had read the ICJME criteria.[fifty]

[edit]

If a written report requires exterior funding, this can be a major source of conflicting interests; for instance in cases where the manufacturer of a drug is funding a study into its safety and efficacy[14] or where the sponsor hopes to use the enquiry to defend itself in litigation.[54] Sponsors of a written report may involve themselves in the design, execution, analysis, and write-upwards of a study. In extreme cases, they may bear out the enquiry and ghostwrite the commodity with well-nigh no interest from the nominal author.[53] [52] Moving-picture show-style credits are advocated as a style to avoid this.[51]

There are many opportunities for bias in trial pattern and trial reporting. For example, a trial that compares a drug against the wrong dose of a competing drug may produce spuriously positive results.[55]

In some cases, a contract with a sponsor may mean those named as investigators and authors on the papers may not have access to the trial data, control over the publication text, or the freedom to talk about their work.[56] While authors and institutions have an involvement in avoiding such contracts, it conflicts with their involvement in competing for funding from potential report sponsors.[58] Institutions that fix stricter ethical standards for sponsor contracts lose contracts and funding when sponsors go elsewhere.[56]

Sponsors accept required contractual promises that the study is not reported without the sponsor'due south approval (gag clauses)[56] [59] and some have sued authors over compliance.[60] [59] Trials may get unpublished to continue commercial data secret or because the trial results were unfavourable.[61] Some journals require that man trials be registered to be considered for publication;[61] some crave the declaration of whatsoever gag clauses as a conflict of interest;[1] : 4 since 2001, some as well require a statement that the authors have not agreed to a gag clause.[56] Some journals crave a promise to provide admission to the original data to researchers intending to replicate the piece of work.[62] Some research ethics boards,[63] universities,[59] and national laws[64] prohibit gag clauses. Gag clauses may non be legally enforceable if compliance would cause sufficient public harm.[59] Non-publication has been institute to exist more common in manufacture-funded trials, contributing to publication bias.[63]

It has been suggested that having many sponsors with different interests protects against COI-induced bias. Every bit of 2006[update], there was no evidence for or confronting this hypothesis.[39]

Effect on conclusions of research [edit]

There is evidence that industry funding of studies of medical devices and drugs results in these studies having more positive conclusions regarding efficacy (funding bias).[65] A like relationship has been found in clinical trials of surgical interventions, where industry funding leads to researchers exaggerating the positive nature of their findings.[66] Not all studies accept found a statistically pregnant human relationship betwixt industry funding and the study event.[67] [68]

Interests of research participants [edit]

Chronically ill medical research participants written report expectation of being told nearly COIs and some study they would not participate if the researcher had some sorts of COIs.[39] With few exceptions, multiple ethical guidelines preclude researchers with a fiscal interest in the outcome from being involved in human trials.[iii]

The consent agreements entered into with study participants may be legally bounden on the academics but not on the sponsor, unless the sponsor has a contractual commitment maxim otherwise.[69]

Ethical rules, including the Declaration of Helsinki, crave the publication of results of human trials.[61] participants in which are oftentimes motivated by a desire to better medical knowledge.[70] Patients may be harmed if safety data, such risks to patients, are kept secret. Duties to human being-inquiry participants can therefore conflict with interests in non-publication such every bit gag clauses.[56]

Publication of COI declarations [edit]

Some journals place COI declarations at the beginning of an article simply near put it in smaller impress at the cease.[39] Positioning makes a departure; if readers feel they are being manipulated from the first of a text, they read more critically than if the same feeling is produced at the end of a text.[71]

Co-ordinate to the ICMJE, "each periodical should develop standards with regard to the grade the [COI] information should have and where it will be posted".[1] It is ofttimes placed afterwards the body of the article, just before the reference section.[72] Some COI statements, like those of bearding reviewers, may not exist published at all. (see § COIs of peer reviewers) COI statements are sometimes paywalled so they are just visible to those who take paid for full text access.[73] [74] This is not considered ethical by the Commission on Publication Ethics.[31]

In 2017 PubMed began including COI statements at the end of the abstruse and before the body of the commodity[72] after receiving complaints that because COI declarations were only included in total article texts, they often went unseen in paywalled articles.[74] Only COI statements that are appropriately formatted and tagged past the publisher are included.[75]

Science journalism rarely reports COI data from the academic article reported upon; in some studies, fewer than 1% of stories included COI data.[2]

False statements of COIs [edit]

Failure to disclose a conflict of interest may, depending on the circumstances, be considered a grade of corruption[76] or academic misconduct.[77]

Meet also [edit]

  • Academic authorship
  • Metascience

References [edit]

  1. ^ a b c d e f yard h Fees, F. (2016), Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals (PDF) Conflicts-of-interest section, [Last update on 2015 December].
  2. ^ a b c d e f m h i Dunn, Adam One thousand.; Coiera, Enrico; Mandl, Kenneth D.; Bourgeois, Florence T. (2016-05-03). "Conflict of involvement disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency". Research Integrity and Peer Review. 1: 1. doi:x.1186/s41073-016-0006-seven. PMC4854425. PMID 27158530.
  3. ^ a b c d east f chiliad Institute of Medicine (United states) Committee on Conflict of Interest in Medical Research, Education, and Practice (2009). Lo, Bernard; Field, Marilyn J. (eds.). Conflict of Interest in Medical Enquiry, Education, and Exercise. The National Academies Collection: Reports funded past National Institutes of Health. Washington (DC): National Academies Press (United states of america). ISBN978-0-309-13188-ix. PMID 20662118. {{cite book}}: CS1 maint: multiple names: authors list (link)
  4. ^ a b c d due east f chiliad h Rosenbaum, Lisa (2015-05-21). "Beyond Moral Outrage — Weighing the Trade-Offs of COI Regulation". New England Journal of Medicine. 372 (21): 2064–2068. doi:x.1056/NEJMms1502498. PMID 25992752. S2CID 205088730.
  5. ^ a b c Loder, Elizabeth; Brizzell, Catherine; Godlee, Fiona (2015-06-02). "Revisiting the commercial-academic interface in medical journals". BMJ. 350: –2957. doi:10.1136/bmj.h2957. PMID 26037508. Retrieved 2018-03-29 .
  6. ^ Matheson, Alastair (2011-08-09). "How Industry Uses the ICMJE Guidelines to Dispense Authorship—And How They Should Exist Revised". PLOS Medicine. 8 (viii): –1001072. doi:ten.1371/journal.pmed.1001072. PMC3153455. PMID 21857808.
  7. ^ Council of Scientific discipline Editors' Editorial Policy Committee (2011-2012) (2012-03-xxx). White Paper on Publication Ethics (2012 update). Council of Science editors. Retrieved 2018-04-thirty .
  8. ^ Battisti, Wendy P.; Wager, Elizabeth; Baltzer, Lise; Bridges, Dan; Cairns, Angela; Carswell, Christopher I.; Citrome, Leslie; Gurr, James A.; Mooney, LaVerne A.; Moore, B. Jane; Peña, Teresa; Sanes-Miller, Carol H.; Veitch, Keith; Woolley, Karen L.; Yarker, Yvonne E. (2015-09-fifteen). "Good Publication Exercise for Communicating Visitor-Sponsored Medical Research: GPP3". Annals of Internal Medicine. 163 (6): 461–4. doi:10.7326/M15-0288. PMID 26259067. (institutional link)
  9. ^ Committee on Publication Ethics (COPE), Core practices , retrieved 2018-04-30
  10. ^ Laine, Christine; Winker, Margaret A. (2017-02-18). "Identifying Predatory or Pseudo-Journals". Retrieved 2018-03-28 .
  11. ^ Redhead, Claire (2013-12-19). "Principles of Transparency and Best Practice in Scholarly Publishing - OASPA". Retrieved 2018-03-28 .
  12. ^ a b c Kojima, Takako; Light-green, Joseph; Barron, J. Patrick (2015-08-01). "Conflict-of-interest disclosure at medical journals in Nihon: a nationwide survey of the practices of periodical secretariats". BMJ Open. v (eight): –007957. doi:10.1136/bmjopen-2015-007957. PMC4554913. PMID 26310399.
  13. ^ The PLoS Medicine Editors (2010-10-26). "Increased Responsibility and Transparency in an Era of Increased Visibility". PLOS Medicine. 7 (10): –1000364. doi:10.1371/journal.pmed.1000364. PMC2964334. PMID 21048984.
  14. ^ a b c d eastward f 1000 h i Lundh, Andreas; Barbateskovic, Marija; Hróbjartsson, Asbjørn; Gøtzsche, Peter C. (2010-10-26). "Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Periodical Touch Factors and Revenue – Accomplice Report". PLOS Medicine. seven (10): –1000354. doi:x.1371/journal.pmed.1000354. PMC2964336. PMID 21048986.
  15. ^ a b Fletcher, Suzanne Westward; Fletcher, Robert H (March 1999). "Medical Editors, Periodical Owners, and the Sacking of George Lundberg" (PDF). Journal of Full general Internal Medicine. fourteen (3): 200–202. doi:10.1046/j.1525-1497.1999.00347.10. PMC1496545. PMID 10203629.
  16. ^ a b c d e f Ray, J. G. (2002-12-01). "Judging the judges: the part of periodical editors". QJM: An International Journal of Medicine. 95 (12): 769–774. doi:x.1093/qjmed/95.12.769. PMID 12454319.
  17. ^ a b Marcovitch, Harvey (2010-10-26). "Editors, Publishers, Impact Factors, and Reprint Income". PLOS Medicine. vii (10): –1000355. doi:10.1371/journal.pmed.1000355. PMC2964337. PMID 21048987.
  18. ^ Reingewertz, Yaniv; Lutmar, Carmela (2017-04-05). Academic In-Group Bias: An Empirical Test of the Link between Author and Journal Amalgamation. SSRN 2946811.
  19. ^ Flaherty, Coleen (2018-03-02). "Study finds evidence of institutional favoritism in bookish publishing". Retrieved 2018-03-27 .
  20. ^ Davis, Ronald M.; Neale, Anne Victoria; Monsur, Joseph C. (December 2003). "Medical journals' conflicts of interest in the publication of book reviews". Science and Engineering Ethics. 9 (4): 471–483. doi:10.1007/s11948-003-0045-6. PMID 14652900. S2CID 32068696.
  21. ^ Peter Suber; et al., "Journal declarations of independence", Open Access Directory , retrieved 2018-03-28
  22. ^ Mark C. Wilson (2016-10-08). "What happens to journals that interruption away?". Filling a much-needed gap . Retrieved 2018-03-28 .
  23. ^ a b Hoey, John (1999-09-07). "When journals are branded, editors get burnt: the ousting of Jerome Kassirer from the New England Journal of Medicine". Canadian Medical Association Periodical. 161 (v): 529–530. PMC1230583. PMID 10497610. Retrieved 2018-03-27 .
  24. ^ a b c d e Smith, Richard (2010-xi-02). "Richard Smith on editors' conflicts of involvement – The BMJ". Retrieved 2018-03-29 .
  25. ^ Nestle, Marion (23 June 2015). "Conflicts of interest in nutrition societies: American Order of Nutrition". Marion Nestle. Retrieved twenty November 2013.
  26. ^ a b c Commissioner, Office of the (Jan 2009), Adept Reprint Practices for the Distribution of Medical Journal Manufactures and Medical or Scientific Reference Publications on Unapproved New Uses of Canonical Drugs and Canonical or Cleared Medical Devices (FDA Guidance Document), retrieved 2018-04-30
  27. ^ Ornstein, Charles (2016-04-05). "Amid Public Feuds, A Venerated Medical Journal Finds…" (text/html). ProPublica . Retrieved 2018-03-29 .
  28. ^ Wilhite, A. W.; Fong, E. A. (2012). "Coercive Citation in Academic Publishing". Scientific discipline. 335 (6068): 542–3. Bibcode:2012Sci...335..542W. doi:10.1126/science.1212540. PMID 22301307. S2CID 30073305.
  29. ^ Smith, Richard (1997). "Journal accused of manipulating impact factor". BMJ. 314 (7079): 463. doi:10.1136/bmj.314.7079.461d. PMC2125988. PMID 9056791.
  30. ^ Wilhite, A. W.; Fong, East. A. (2012). "Coercive Citation in Academic Publishing". Scientific discipline. 335 (6068): 542–iii. Bibcode:2012Sci...335..542W. doi:10.1126/science.1212540. PMID 22301307. S2CID 30073305.
  31. ^ a b c d Allison, David B.; Brown, Andrew West.; George, Brandon J.; Kaiser, Kathryn A. (4 Feb 2016). "Reproducibility: A tragedy of errors". Nature News. 530 (7588): 27–9. Bibcode:2016Natur.530...27A. doi:10.1038/530027a. PMC4831566. PMID 26842041.
  32. ^ "Retraction challenges". Nature News. 514 (7520): five. 2 October 2014. Bibcode:2014Natur.514Q...five.. doi:ten.1038/514005a. PMID 25279879.
  33. ^ Flanagin, Annette; Carey, Lisa A.; Fontanarosa, Phil B.; Phillips, Stephanie K.; Pace, Brian P.; Lundberg, George D.; Rennie, Drummond (1998-07-15). "Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals". JAMA. 280 (iii): 222–224. doi:ten.1001/jama.280.3.222. PMID 9676661.
  34. ^ Nestle, Marion (two January 2007). "Food company sponsorship of nutrition research and professional activities: a disharmonize of interest?" (PDF). Public Wellness Nutrition. iv (5): 1015–1022. doi:10.1079/PHN2001253. PMID 11784415.
  35. ^ Goldacre, Ben (May nine, 2009). "The danger of drugs … and data". The Guardian. London. ISSN 0261-3077. Archived from the original on 17 November 2009. Retrieved Nov 20, 2009.
  36. ^ a b "Conflict of Interest in Peer-Reviewed Medical Journals". 2009. Retrieved 2018-03-28 .
  37. ^ a b Liu, Jessica J.; Bong, Chaim M.; Matelski, John J.; Detsky, Allan S.; Cram, Peter (2017-ten-26). "Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational report". BMJ. 359: –4619. doi:10.1136/bmj.j4619. PMC5655612. PMID 29074628.
  38. ^ McCook, Writer Alison (2017-11-08). "Near editors of top medical journals receive industry payments: report". Retraction Watch . Retrieved 2018-03-28 .
  39. ^ a b c d e Bastian, Hilda (Dec 2006). "'They would say that, wouldn't they?' A reader's guide to author and sponsor biases in clinical inquiry". Journal of the Royal Society of Medicine. 99 (12): 611–614. doi:10.1258/jrsm.99.12.611. PMC1676333. PMID 17139062.
  40. ^ a b Resnik, David B.; Elmore, Susan A. (February 2018). "Disharmonize of Interest in Periodical Peer Review". Toxicologic Pathology. 46 (2): 112–114. doi:x.1177/0192623318754792. PMC5825276. PMID 29382273.
  41. ^ Stern, Author Victoria (2017-08-15). "What should journals do when peer reviewers do not disclose potential conflicts?". Retraction Watch . Retrieved 2018-03-28 .
  42. ^ Smith, Richard (April 2006). "Peer review: a flawed process at the center of science and journals". Journal of the Imperial Order of Medicine. 99 (4): 178–182. doi:10.1258/jrsm.99.4.178. PMC1420798. PMID 16574968.
  43. ^ a b "Financial transparency pare-deep at medical journals". Reuters. 2011-06-08. Retrieved 2018-03-27 .
  44. ^ Cynthia Clerk (2017-11-02). "What to do if a reader suspects undisclosed disharmonize of involvement (CoI) in a published article | Committee on Publication Ethics: COPE". Retrieved 2018-03-28 .
  45. ^ Carey, Benedict (2006-07-25). "Correcting the Errors of Disclosure". The New York Times . Retrieved 2018-03-27 .
  46. ^ Wager, Elizabeth; Barbour, Virginia; Yentis, Steven; Kleinert, Sabine (2009). "Retractions: guidance from the Committee on Publication Ethics (COPE)". Maturitas. 64 (4): 201–203. doi:10.1016/j.maturitas.2009.09.018. PMC2802086. PMID 19954902.
  47. ^ a b Stern, Writer Victoria (2017-01-19). "Undisclosed conflicts of involvement ordinarily pb to corrections – just for some journals, that'south not enough". Retraction Watch . Retrieved 2018-03-28 .
  48. ^ Stern, Author Victoria (2018-01-17). "Journal retracts letter for missing disclosure author says he tried to submit". Retraction Watch . Retrieved 2018-03-27 .
  49. ^ a b c Fees, F. (2016), Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals (PDF) Conflicts-of-interest department, [Last update on 2015 Dec]. Subsection: International Committee of Medical Periodical Editors. "ICMJE | Recommendations | Defining the Role of Authors and Contributors". Retrieved 2018-04-30 .
  50. ^ a b c Kornhaber, Rachel Anne; McLean, Loyola M.; Baber, Rodney J. (2015-07-30). "Ongoing ethical problems concerning authorship in biomedical journals: an integrative review". International Journal of Nanomedicine. ten: 4837–46. doi:10.2147/IJN.S87585. PMC4525802. PMID 26257520.
  51. ^ a b Sillender, Mark (2012-01-10). "Why non switch to movie-style credits for enquiry papers?". BMJ. 344: –179. doi:10.1136/bmj.e179. PMID 22235015. S2CID 40991610. Retrieved 2018-03-28 .
  52. ^ a b Stern, Simon; Lemmens, Trudo (2011-08-02). "Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Manufactures". PLOS Medicine. eight (8): –1001070. doi:10.1371/journal.pmed.1001070. PMC3149079. PMID 21829331.
  53. ^ a b Bosch, Xavier; Esfandiari, Bijan; McHenry, Leemon (2012-01-24). "Challenging Medical Ghostwriting in United states Courts". PLOS Medicine. 9 (1): –1001163. doi:10.1371/journal.pmed.1001163. PMC3265530. PMID 22291578.
  54. ^ amarcus41, Author (2012-02-14). "Amid lawsuits, toxicology journal corrects four asbestos papers for failure to cite author links to Georgia-Pacific". Retraction Watch . Retrieved 2018-03-29 .
  55. ^ Smith, Richard (2005). "Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies". PLOS Medicine. 2 (5): e138. doi:ten.1371/periodical.pmed.0020138. PMC1140949. PMID 15916457.
  56. ^ a b c d e Steinbrook, Robert (2005-05-26). "Gag Clauses in Clinical-Trial Agreements". New England Journal of Medicine. 352 (21): 2160–2162. doi:x.1056/NEJMp048353. PMID 15917381.
  57. ^ Meier, Barry (2004-11-29). "Contracts Keep Drug Enquiry Out of Achieve". The New York Times. ISSN 0362-4331. Retrieved 2018-06-07 .
  58. ^ a b c d Schafer, A. (2004-02-01). "Biomedical conflicts of involvement: a defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy". Journal of Medical Ethics. thirty (1): 8–24. doi:10.1136/jme.2003.005702. PMC1757130. PMID 14872066.
  59. ^ Mello, Michelle M.; Clarridge, Brian R.; Studdert, David G. (2005-05-26). "Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry". New England Journal of Medicine. 352 (21): 2202–2210. doi:10.1056/NEJMsa044115. PMID 15917385. S2CID 8283797.
  60. ^ a b c Jones, Christopher W.; Handler, Lara; Crowell, Karen E.; Keil, Lukas G.; Weaver, Mark A.; Platts-Mills, Timothy F. (2013-x-29). "Non-publication of large randomized clinical trials: cantankerous sectional analysis". BMJ. 347: –6104. doi:10.1136/bmj.f6104. PMC3812466. PMID 24169943.
  61. ^ Thomas, Katie (2013-06-29). "Breaking the Seal on Drug Research". The New York Times . Retrieved 2018-03-29 .
  62. ^ a b Hall, Richard; de Antueno, Cecilia; Webber, Adam (May 2007). "Publication bias in the medical literature: A review past a Canadian research ethics board". Canadian Journal of Anesthesia. 54 (5): 380–388. doi:10.1007/BF03022661. PMID 17470890.
  63. ^ Groves, Trish (2008-01-24). "Mandatory disclosure of trial results for drugs and devices". BMJ. 336 (7637): 170. doi:10.1136/bmj.39469.465139.80. PMC2213793. PMID 18219000.
  64. ^ Lundh, Andreas; Lexchin, Joel; Mintzes, Barbara; Schroll, Jeppe B.; Bero, Lisa (2017-02-16). "Industry sponsorship and enquiry outcome". Cochrane Database of Systematic Reviews. 2: MR000033. doi:10.1002/14651858.mr000033.pub3. PMC8132492. PMID 28207928.
  65. ^ Probst, Pascal; Knebel, Phillip; Grummich, Kathrin; Tenckhoff, Solveig; Ulrich, Alexis; Büchler, Markus West.; Diener, Markus K. (July 2016). "Industry Bias in Randomized Controlled Trials in General and Abdominal Surgery". Annals of Surgery. 264 (1): 87–92. doi:10.1097/sla.0000000000001372. ISSN 0003-4932. PMID 26465782. S2CID 7863563.
  66. ^ Chartres, Nicholas; Fabbri, Alice; Bero, Lisa A. (2016-12-01). "Clan of Manufacture Sponsorship With Outcomes of Nutrition Studies". JAMA Internal Medicine. 176 (12): 1769–1777. doi:10.1001/jamainternmed.2016.6721. ISSN 2168-6106. PMID 27802480.
  67. ^ Voineskos, Sophocles H.; Coroneos, Christopher J.; Ziolkowski, Natalia I.; Kaur, Manraj N.; Banfield, Laura; Meade, Maureen O.; Chung, Kevin C.; Thoma, Achilleas; Bhandari, Mohit (Feb 2016). "A Systematic Review of Surgical Randomized Controlled Trials". Plastic and Reconstructive Surgery. 137 (ii): 453e–461e. doi:ten.1097/01.prs.0000475767.61031.d1. ISSN 0032-1052. PMID 26818335. S2CID 7822229.
  68. ^ Mello, Michelle M.; Joffe, Steven (2007). "Compact versus Contract-Manufacture Sponsors' Obligations to Their Research Subjects". New England Journal of Medicine. 356 (26): 2737–43. doi:10.1056/NEJMhle067499. PMID 17596610. S2CID 20761967.
  69. ^ Inquiry, Center for Drug Evaluation and (2014-eleven-06). "Data for Consumers (Drugs) - Inside Clinical Trials: Testing Medical Products in People" (WebContent). FDA.gov . Retrieved 2018-03-29 .
  70. ^ Silvia, Paul J. (2006). "Reactance and the dynamics of disagreement: Multiple paths from threatened freedom to resistance to persuasion" (PDF). European Journal of Social Psychology. 36 (5): 673–685. doi:ten.1002/ejsp.309.
  71. ^ a b Belluz, Julia (2017-04-xix). "Also many studies have hidden conflicts of involvement. A new tool makes it easier to see them". Vox . Retrieved 2018-06-07 .
  72. ^ amarcus41, Author (2013-11-06). ""Personal rivalry" leads to retraction of nut-health newspaper". Retraction Picket . Retrieved 2018-03-30 .
  73. ^ a b Office of Richard Blumenthal (United States Senator) (2016-03-30). "Blumenthal, Colleagues Urge Clear Disclosure of Conflicts of Involvement in Scientific Papers" (Printing release) . Retrieved 2018-06-07 .
  74. ^ Robertson, Christopher (20 April 2017). "Conflict of Interests Disclosures Come to PubMed". Bill of Wellness. Petrie-Flom Centre, Harvard Law School.
  75. ^ Independent Commission Against Corruption. "Knowing your risks". Retrieved 2018-04-thirty .
  76. ^ Koocher, Gerald P.; Keith-Spiegel, Patricia (July 22, 2010). "Peers nip misconduct in the bud". Nature. 466 (7305): 438–440. Bibcode:2010Natur.466..438K. doi:10.1038/466438a. ISSN 0028-0836. PMID 20651674. S2CID 4396687.

External links [edit]

  • Responsible Conduct of Research: Conflicts of Interest. Online course, Columbia Academy.

costellothentorcip.blogspot.com

Source: https://en.wikipedia.org/wiki/Conflicts_of_interest_in_academic_publishing

0 Response to "4 Review Conflict-of-interest Statements Obtained by the Company for Its Management"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel